Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OmniAbOABI +3.93%69 OCF Margin % is 19.97% as of Jun. 2026. GuruFocus rates OABI with a GF Score™ of 69/100 and a GF Value™ of $2.91 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 956 Biotechnology companies, OmniAb ranks better than 53.14% on this metric.
The historical data trend for OmniAb's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, OmniAb's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OmniAb OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OmniAb's OCF Margin % distribution charts can be found below:
* The bar in red indicates where OmniAb's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OmniAb (OABI) has a OCF Margin % of 19.97% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on OmniAb and its competitors. According to the industry distribution chart, OmniAb ranks #448 out of 956 companies in the Biotechnology industry, placing it in the top 46.9%.
Is OmniAb's OCF Margin % too high?
OmniAb's current OCF Margin % is 19.97%. Based on the distribution chart, OmniAb ranks #448 out of 956 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OmniAb has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OmniAb's OCF Margin % compare to FHTX and PRLD?
According to the Biotechnology industry distribution chart, OmniAb ranks #448 out of 956 companies for OCF Margin %. This puts OmniAb in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on OmniAb and its competitors. OmniAb's current OCF Margin % is 19.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OmniAb stock overvalued right now?
Based on GuruFocus' analysis, OmniAb (OABI) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.91, compared to a current price of $3.97 — trading 36.4% above its estimated fair value. The current OCF Margin % is 19.97%. OmniAb's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For OmniAb (OABI), the current OCF Margin % is 19.97% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OmniAb (OABI) Overvalued in 2026?
Based on GuruFocus' analysis, OmniAb stock appears to be overvalued.
The current stock price of $3.97 is trading 36.4% above its estimated GF Value™ of $2.91.
GuruFocus considers OmniAb to be Significantly Overvalued.
Key valuation signals for OABI:
OCF Margin %: 19.97%
GF Value™: $2.91 vs. price of $3.97 (36.4% above fair value)
No single metric tells the full story. See the OABI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
69GF Score
Get the complete analysis for OABI
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OABI has been successfully added to your 
